Strategies to further improve the delivery of RNAi therapeutics

In order to understand how cells internalize small interfering RNAs (siRNAs), we followed the delivery of lipid nanoparticles loaded with siRNAs in the mouse liver tissue, in collaboration with Alnylam Pharmaceuticals. Using quantitative imaging and electron microscopy, we monitored the uptake and intracellular trafficking of these particles and found that the mechanism of uptake is cell type dependent. These data can contribute to designing strategies for cell-specific siRNA delivery, with direct pharmaceutical implications. Read more about this in the press release of MPI-CBG or download the original paper published in Nature Biotechnology last month.